Aricioğlu Feyza, Yalcinkaya Canan, Ozkartal Ceren Sahin, Tuzun Erdem, Sirvanci Serap, Kucukali Cem Ismail, Utkan Tijen
Department of Pharmacology and Psychopharmacology Research Unit, School of Pharmacy, Marmara University Istanbul, Turkey.
Department of Neuroscience, Istanbul University Institute of Experimental Medical Research, Istanbul, Turkey.
Psychiatry Investig. 2020 Apr;17(4):283-291. doi: 10.30773/pi.2019.0189. Epub 2020 Mar 24.
NOD-like receptor protein 1 (NLRP1) inflammasome complex has been recently associated with chronic unpredictable mild stress (CUMS) model of depression. Our aim was to investigate whether ketamine-induced antidepressant effect is associated with suppression of NLRP1.
Wistar albino rats were divided into control, CUMS, CUMS+acute ketamine (a single 10 mg/kg dose) and CUMS+chronic ketamine (daily 10 mg/kg injections for 3 weeks) groups (n=10 for each group). Sucrose preference test and forced swimming test were performed to assess anhedonia and immobility time respectively for the severety of depression symptoms. Brain tissues were dissected and prefrontal cortex and hippocampus regions were used for real-time polymerase chain reaction (PCR) and immunohistochemical analysis.
CUMS procedure significantly induced depressive-like symptoms whereas both acute and chronic ketamine treatment ameliorated them. mRNA expression levels of NLRP1, caspase 1, apoptosis-associated speck-like protein containing a CARD (ASC), NF-κB, endothelial nitric oxide synthase, IL-1β, IL-6, toll-like receptor 4 (TLR-4) and purinergic 2×7 receptor (P2X7R) and numbers of Iba- 1+and GFAP+glial cells were reduced by acute and/or chronic ketamine treatment.
In the present study for the first time upstream and downstream elements of the NLRP1 inflammasome complex are shown to be suppressed by ketamine thus reinforcing the involvement of NLRP1 in the physiopathology of depression.
核苷酸结合寡聚化结构域样受体蛋白1(NLRP1)炎性小体复合物最近被认为与抑郁症的慢性不可预测轻度应激(CUMS)模型有关。我们的目的是研究氯胺酮诱导的抗抑郁作用是否与NLRP1的抑制有关。
将Wistar白化大鼠分为对照组、CUMS组、CUMS+急性氯胺酮组(单次10mg/kg剂量)和CUMS+慢性氯胺酮组(每日10mg/kg注射3周)(每组n=10)。分别进行蔗糖偏好试验和强迫游泳试验,以评估快感缺失和不动时间,从而判断抑郁症状的严重程度。解剖脑组织,前额叶皮质和海马区用于实时聚合酶链反应(PCR)和免疫组织化学分析。
CUMS程序显著诱发了抑郁样症状,而急性和慢性氯胺酮治疗均改善了这些症状。急性和/或慢性氯胺酮治疗降低了NLRP1、半胱天冬酶1、含CARD的凋亡相关斑点样蛋白(ASC)、核因子κB、内皮型一氧化氮合酶、白细胞介素-1β、白细胞介素-6、Toll样受体4(TLR-4)和嘌呤能2X7受体(P2X7R)的mRNA表达水平,以及Iba-1+和GFAP+神经胶质细胞的数量。
在本研究中,首次表明氯胺酮可抑制NLRP1炎性小体复合物的上游和下游元件,从而加强了NLRP1在抑郁症病理生理学中的作用。